Scinai Immunotherapeutics Ltd. SCNI
NASDAQ
Recommendation
Dividend Power Score
Day's Range
$0.52$0.57
Latest Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
EPS (TTM)
| 06/30/2026 | 12/31/2025 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | 145.99% | 30.58% | -34.15% | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 145.99% | 30.58% | -34.15% | ||
| Cost of Revenue | 1.60% | 157.37% | 276.12% | ||
| Gross Profit | 16.42% | -313.77% | -813.41% | ||
| SG&A Expenses | -9.54% | -16.67% | 45.47% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 9.40% | -12.58% | 3.07% | ||
| Operating Income | 2.23% | 16.50% | -8.29% | ||
| Income Before Tax | 22.27% | 6.43% | -10.98% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 22.27% | 6.43% | -10.98% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 22.27% | 6.43% | -10.98% | ||
| EBIT | 2.23% | 16.50% | -8.29% | ||
| EBITDA | 15.31% | 13.21% | -20.31% | ||
| EPS Basic | 91.39% | 88.08% | 43.51% | ||
| Normalized Basic EPS | 90.34% | 95.07% | 43.51% | ||
| EPS Diluted | 91.39% | 88.08% | 43.51% | ||
| Normalized Diluted EPS | 90.34% | 95.07% | 43.51% | ||
| Average Basic Shares Outstanding | 802.47% | 149.11% | 96.39% | ||
| Average Diluted Shares Outstanding | -- | -- | -- | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||